IntriCon (NasdaqGM:IIN) - Share price, News & Analysis

IIN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

IIN Stock Overview

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally.

Rewards

Earnings are forecast to grow 122.13% per year

Risk Analysis

Shareholders have been diluted in the past year

IntriCon Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IntriCon
Historical stock prices
Current Share Price	US$24.24
52 Week High	US$25.15
52 Week Low	US$12.47
Beta	1.01
1 Month Change	1.00%
3 Month Change	44.11%
1 Year Change	1.13%
3 Year Change	-0.33%
5 Year Change	178.62%
Change since IPO	337.41%

Shareholder Returns

	IIN	US Medical Equipment	US Market
7D	0.9%	2.9%	5.9%
1Y	1.1%	-14.9%	-10.2%

Return vs Industry: IIN exceeded the US Medical Equipment industry which returned -15.7% over the past year.

Return vs Market: IIN exceeded the US Market which returned -12.3% over the past year.

Price Volatility

Is IIN's price volatile compared to industry and market?
IIN volatility
IIN Average Weekly Movement	10.8%
Medical Equipment Industry Average Movement	10.5%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: IIN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IIN's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1930	873	J. Longval	https://www.intricon.com

IntriCon Corporation, together with its subsidiaries, designs, develops, engineers, manufactures, and distributes body-worn devices in the United States, Europe, Asia, and internationally. It offers micro-miniature products, microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components, and assemblies and software solutions for medical devices, hearing healthcare, and professional audio communication devices markets. The company also provides micro coils for surgical navigation clinical applications, such as interventional pulmonology and electrophysiology; joint engineering and manufacturing services for complex medical devices, including catheters covering a range of applications for cardiology, peripheral vascular, neurology, radiology, and pulmonology; bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system; and safety needle products for original equipment manufacturing customers.

IntriCon Fundamentals Summary

How do IntriCon's earnings and revenue compare to its market cap?
IIN fundamental statistics
Market Cap	US$225.49m
Earnings (TTM)	-US$1.48m
Revenue (TTM)	US$126.50m

1.8x

P/S Ratio

-152.7x

P/E Ratio

Is IIN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IIN income statement (TTM)
Revenue	US$126.50m
Cost of Revenue	US$94.45m
Gross Profit	US$32.05m
Other Expenses	US$33.52m
Earnings	-US$1.48m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.16
Gross Margin	25.33%
Net Profit Margin	-1.17%
Debt/Equity Ratio	0%

How did IIN perform over the long term?

See historical performance and comparison

Valuation

Is IntriCon undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

2.41x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IIN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IIN's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: IIN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.

PE vs Market: IIN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IIN's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: IIN's Price-To-Book Ratio (2.4x) is in line with the US Medical Equipment industry average.

Future Growth

How is IntriCon forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

122.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IIN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: IIN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IIN's is expected to become profitable in the next 3 years.

Revenue vs Market: IIN's revenue (14.1% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: IIN's revenue (14.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IIN's Return on Equity is forecast to be high in 3 years time

Past Performance

How has IntriCon performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-25.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IIN is currently unprofitable.

Growing Profit Margin: IIN is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IIN is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.

Accelerating Growth: Unable to compare IIN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IIN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).

Return on Equity

High ROE: IIN has a negative Return on Equity (-1.42%), as it is currently unprofitable.

Financial Health

How is IntriCon's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: IIN's short term assets ($76.6M) exceed its short term liabilities ($23.9M).

Long Term Liabilities: IIN's short term assets ($76.6M) exceed its long term liabilities ($8.8M).

Debt to Equity History and Analysis

Debt Level: IIN is debt free.

Reducing Debt: IIN has no debt compared to 5 years ago when its debt to equity ratio was 65.7%.

Debt Coverage: IIN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IIN has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is IntriCon current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IIN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IIN's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IIN has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure

CEO

J. Longval (44 yo)

1.58yrs

Tenure

US$1,296,997

Compensation

Mr. J. Scott Longval has been Chief Executive Officer, President and Director of IntriCon Corporation since October 1, 2020. He served as an Executive Vice President at IntriCon Corporation until September...

CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD1.30M) is about average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: J.'s compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: IIN's management team is considered experienced (2.1 years average tenure).

Board Members

Experienced Board: IIN's board of directors are considered experienced (4.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.5%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31